Skip to comments.Indian scientist develops potential non-insulin diabetes drug
Posted on 04/03/2014 7:56:42 PM PDT by Pining_4_TX
"We find that there is a peptide hormone in the gut called GLP1 that increases the secretion of insulin only when the blood glucose is high. This effectively eliminates the risk of hypoglycemic shock. Another advantage is that GLP1 administration has been found to stimulate weight-loss. The hormone offers the promise of revolutionising the treatment of Type II diabetes and reduce obesity," he said.
(Excerpt) Read more at financialexpress.com ...
Please let others know who might be interested in this article. Thanks!
Half-life of two minutes makes it really difficult to be useful...
Yes, but that is what they are attempting to solve, and they seem to have made progress toward that end.
Hope springs eternal, as they say. :-)
If this turns out to be true, it is a great discovery.
Yes it would. I keep hoping for something that gives us more than just healthier mice. ;-)
Exactly, hope this comes to America.
It’s a huge industry killer. Just imagine if they could end type II with a single weekly pill that not only lowers your blood sugar, but reduces your weight and makes you healthier?
I hope these scientists don’t find themselves on a dissapearing 777.
“I hope these scientists dont find themselves on a dissapearing 777.”
Now that’s a disturbing thought.
Wonderful news he should win Nobel Prize.
Interesting development.... worth keeping an eye on
Patient compliance would be astronomically high.
This article is a joke. GLP-1 (glucagon like polpypetide 1) was discovered about 25 years ago. It lowers blood sugar and the human gut secretes it naturally, but it has a short half-life, because it is inactivated by DPP4 (dipeptidyl peptidase 4), another naturally occurring enzyme in the human body. Januvia (by Merck) was the first DPP-4 inhibitor, used to block the DPP-4 enzyme’s degradation of GLP-1, thus lowering blood sugar. Next came a natural mimetic (copy) of GLP-1, Byetta, and it’s analog (synthetic) twin Bydureon, both owned by Astra Zeneca. These drugs came out in the mid 2000’s. Another GLP-1 analog, Victoza (from Novo Nordisk) came out in 2010. There are also a host of Januvia copies on the market (saxagliptin, alogliptin, linogliptin,etc.). Before you start thinking this is a new breakthrough, educate yourselves on the diabetes therapies.
LOL, threatened much?
With all your big words, you think there’s been no progress since the mid-2000’s?
Or is it that you think that research should just stop where it is, because there’s nothing left to discover or develop?
Or, rather, have your employers told you to squelch hope for your 13 coins of silver?
We have it. It’s called Byetta.
Not sure how this is any different. They’re both GLP-1.
No, he’s right. This is old news.
No, I'm right. The posted date is April 2. That means my points stand. Thanks for playing.
GLP-1 as a treatment for diabetes is old news. This ‘discovery’ is a crock. This would be like someone crowing that they’ve discovered insulin.
Not only has it already been discovered, it’s been tested, developed into a medication, is already on the market, and covered by insurance.
I see where you found the article interesting and wanted to pass it on. I don’t see why this would anger anyone. It was presented as a discovery and you didn’t know. No big deal.
But the fact is, GLP-1 for the treatment of diabetes has been around for awhile. That’s just a fact.
You need to contact the researchers in this field - they have no idea the science is settled and no further development is possible. Please save them from unavoidable terminal frustration, not to mention all the continuously wasted tax dollars. It’s your duty to Truth.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.